News and Analysis

SAB Biotherapeutics nabs $14m Series B

Sioux Falls, South Dakota-based SAB Biotherapeutics, a clinical-stage biopharmaceutical company, has raised $14 million in Series B funding.

-

Sioux Falls, South Dakota-based SAB Biotherapeutics, a clinical-stage biopharmaceutical company, has raised $14 million in Series B funding. The investors included Merck and South Dakota Equity Partners.

Source: Press Release